UK cost agency endorses Novartis heart drug for some patients

Novartis’s big new drug hope Entresto has been recommended for use in some patients with heart failure by Britain’s cost agency NICE, which said on Friday it believed the treatment was a cost-effective option. Entresto has a list price of 1,194 pounds ($1,809) a year in Britain, or less than half the price of $4,560 charged by Novartis in the United States. The National Institute for Health and Care Excellence (NICE) said Entresto was suitable for a subset of heart failure patients whose hearts were particularly poor at pumping blood.

See the original post here:
UK cost agency endorses Novartis heart drug for some patients